Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Strs Ohio

Strs Ohio reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 227,618 shares of the medical research company's stock after selling 7,974 shares during the period. Thermo Fisher Scientific accounts for about 0.5% of Strs Ohio's portfolio, making the stock its 29th largest holding. Strs Ohio owned approximately 0.06% of Thermo Fisher Scientific worth $120,817,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Bornite Capital Management LP boosted its holdings in shares of Thermo Fisher Scientific by 50.0% during the 1st quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company's stock worth $17,719,000 after purchasing an additional 10,000 shares during the last quarter. Fairfield Bush & CO. raised its position in shares of Thermo Fisher Scientific by 1.2% during the 1st quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company's stock valued at $1,729,000 after buying an additional 36 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Thermo Fisher Scientific by 563.5% during the 1st quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company's stock valued at $11,721,000 after buying an additional 16,853 shares during the period. Covestor Ltd raised its position in shares of Thermo Fisher Scientific by 60.5% during the 1st quarter. Covestor Ltd now owns 321 shares of the medical research company's stock valued at $190,000 after buying an additional 121 shares during the period. Finally, Merit Financial Group LLC raised its position in shares of Thermo Fisher Scientific by 3.6% during the 1st quarter. Merit Financial Group LLC now owns 669 shares of the medical research company's stock valued at $395,000 after buying an additional 23 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company's stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last 90 days. Corporate insiders own 0.32% of the company's stock.

Thermo Fisher Scientific Stock Down 1.6 %

Shares of TMO stock traded down $9.34 on Friday, reaching $565.23. 1,201,602 shares of the stock were exchanged, compared to its average volume of 1,177,754. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The business's 50 day moving average price is $571.66 and its 200 day moving average price is $526.14. The company has a market capitalization of $215.76 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 2.38 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts' consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company's revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.40 earnings per share. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's dividend payout ratio is currently 10.10%.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. HSBC assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 18th. They set a "buy" rating and a $610.00 price target on the stock. Barclays lowered shares of Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Citigroup started coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a "neutral" rating and a $620.00 target price on the stock. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a research report on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $601.56.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.